Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune ...

Retail trader buzz around Replimune Group surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ...

Fintel reports that on July 30, 2025, Cantor Fitzgerald upgraded their outlook for Replimune Group (NasdaqGS:REPL) from ...

Replimune (NASDAQ:REPL) stock surges as Cantor Fitzgerald upgrades, citing improved odds for approval of its lead drug after an FDA leadership change. Read more here.

Following a complete response letter rejecting accelerated approval for RP1 in advanced melanoma, IGNYTE trial investigators are urging the FDA to reevaluate the therapy’s robust survival data, just ...

A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks ...

The FDA has issued a CRL to Replimmune regarding the BLA for vusolimogene oderparepvec (RP1) in combination with nivolumab for advanced melanoma.

Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024 and ...

A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges that Defendants ...

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...

In a complete response letter, the FDA indicates the drug trial is not an adequate, well-controlled clinical investigation, ...